SCHEMBL3423749

SCHEMBL3423749

O=C(C=CC1(O)C=CC=CC1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
RECQL P46063 2/20 0.41
PLIN1 O60240 2/20 0.41
LMNA P02545 2/20 0.41
PLIN5 Q00G26 2/20 0.41
ABHD5 Q8WTS1 2/20 0.41
MAOB P27338 2/20 0.41
BCHE P06276 1/20 0.41
TNFRSF1A P19438 1/20 0.41
ACHE P22303 1/20 0.41
CYP1B1 Q16678 1/20 0.41
ALDH1A1 P00352 5/20 0.38
RAB9A P51151 3/20 0.38
HPGD P15428 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
RELA Q04206 2/20 0.38
NPC1 O15118 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6259567 0.81 RECQL (0.41) MAPTRECQLPLIN1LMNAPLIN5
SCHEMBL6470886 0.81 MAPT (0.40) MAPTRECQLPLIN1LMNAPLIN5
SCHEMBL6259565 0.81 RECQL (0.41) MAPTRECQLPLIN1LMNAPLIN5
SCHEMBL3697930 0.81 ALDH1A1 (0.42) MAPTRECQLPLIN1LMNAPLIN5
SCHEMBL4896000 0.81 MAPT (0.44) MAPTRECQLPLIN1LMNAPLIN5
SCHEMBL7965919 0.79
SCHEMBL7965924 0.79
SCHEMBL28068774 0.78 MAPT (0.38) MAPTRECQLPLIN1LMNAPLIN5
SCHEMBL3472865 0.77 AKT1 (0.42) MAPTRECQLPLIN1LMNAPLIN5
SCHEMBL2492193 0.76 MAPT (0.44) MAPTRECQLPLIN1LMNAPLIN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111217690-B Preparation method of propafenone hydrochloride and intermediate 2' -hydroxy dihydrochalcone thereof 临沂大学(CN) 2023-01-13 CN claimed
CN-105796548-A Flavonoid drug composition and preparation method and application 中国科学院西北高原生物研究所 2016-07-27 CN claimed
CN-111217690-B Preparation method of propafenone hydrochloride and intermediate 2' -hydroxy dihydrochalcone thereof 临沂大学(CN) 2023-01-13 CN disclosed
CN-111217690-B Preparation method of propafenone hydrochloride and intermediate 2' -hydroxy dihydrochalcone thereof 临沂大学(CN) 2023-01-13 CN disclosed
CN-111217690-B Preparation method of propafenone hydrochloride and intermediate 2' -hydroxy dihydrochalcone thereof 临沂大学(CN) 2023-01-13 CN disclosed
CN-109310130-B Cooling substance mixture 西姆莱斯股份公司 2022-05-17 CN disclosed
CN-106459123-A Novel substance mixture containing rubusoside or alpha-glucosyl rubusoside for improving sweetness 西姆莱斯股份公司 2017-02-22 CN disclosed
CN-106063504-A Aseptic cheese substrate DMK德意志牛奶股份有限公司 2016-11-02 CN disclosed
US-9445606-B2 Use of 4-hydroxydihydrochalcones and their salts for enhancing an impression of sweetness SYMRISE AG (DE) 2016-09-20 US disclosed
CN-105796548-A Flavonoid drug composition and preparation method and application 中国科学院西北高原生物研究所 2016-07-27 CN disclosed
CN-104886258-A Protein mass to be used as a cheese substitute DMK DEUTSCHES MILCHKONTOR GMBH 2015-09-09 CN disclosed
CN-104719502-A Use of laevulose for improving the sensorial properties of compositions based on acidic whey DMK DEUTSCHES MILCHKONTOR GMBH 2015-06-24 CN disclosed
US-20140135359-A1 METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES MARTINEAU LOUIS C (CA) 2014-05-15 US disclosed
US-20100233102-A1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS SYMRISE GMBH & CO. KG (DE) 2010-09-16 US disclosed
EP-1998636-B1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS SYMRISE GMBH & CO KG (DE) 2010-05-19 EP disclosed
US-20080317923-A1 AROMA COMPOSITION FOR REDUCING OR SUPPRESSING AN UNDESIRED BITTER, ASTRINGENT IMPRESSION SYMRISE GMBH & CO. KG (DE) 2008-12-25 US disclosed
EP-1998636-A1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS Symrise GmbH & Co. KG (DE) 2008-12-10 EP disclosed
CN-100418977-C Fused heterocyclic derivative, pharmaceutical composition containing the same, and pharmaceutical use thereof KISSEI PHARMACEUTICAL (JP) 2008-09-17 CN disclosed
WO-2007107596-A1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS SYMRISE GMBH & CO. KG (DE) 2007-09-27 WO disclosed
CN-1784415-A Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL (JP) 2006-06-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135359-A1 METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES UQCRC2, UQCRC1, TIMM50 MAPT 4702/4885RECQL 350/4885PLIN1 2923/4885
US-20100233102-A1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS TAS2R4, TAS2R1, TAS2R20 MAPT 4633/4885RECQL 1133/4885PLIN1 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.